Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism
- First Online:
In this pilot study, we attempted to determine the optimal dosage regimens of esomeprazole for treatment of GERD with minimal influence of the CYP2C19 polymorphism through a study of the pharmacokinetics and pharmacodynamics of esomeprazole given at 3 different dosage regimens with the same total daily dose.
Each of the 3genotypes of CYP2C19, homozygous extensive metabolizers (homEMs), heterozygous EMS (hetEMs), and poor metabolizers (PMs) were recruited in this clinical trial. Subjects were given a placebo followed by the administration of esomeprazole, at a dose of 40 mg once daily (40QD), 20 mg twice daily (20TD), or 10 mg 4 times daily (10Q4D) for 7 days. Twenty-four-hour and nocturnal intragastric pH and plasma esomeprazole concentrations were all determined on day 7.
The pharmacokinetic parameters and dynamic characteristics differed among the 3 CYP2C19 genotype groups. With esomeprazole 40QD, gastric acid suppression was insufficient to achieve a therapeutic effect, while 20TD and 10Q4D were found to be effective in controlling both daytime and nocturnal gastric acidity for all 3 genotype groups.
It was confirmed that intragastric pH values and plasma esomeprazole concentrations potentially depended on the CYP2C19 genotype status for treatment with esomeprazole. Dosage regimens of divided doses of 20TD or 10Q4D esomeprazole yielded improved antisecretory effects with a minimal influence of CYP2C19 polymorphisms.
KeywordsGERD Esomeprazole CYP2C19 Polymorphism Intragastric pH
- 7.Thomson A, Claar-Nilsson C, Hasselgren G, Niazi M, Rohss K, Nyman L (2000) Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 47(Suppl. 3):A63 (Abstract)Google Scholar
- 11.Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K (2002) Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GORD. J Gastroenterol Hepatol 17(Suppl.):A612 (Abstract)Google Scholar
- 13.Galmiche JP, Bruley S, Varannes DES, Ducrotte P, Sacher-Huvelin S, Vavasseur F et al (2004) Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 19:655–662PubMedCrossRefGoogle Scholar
- 18.Hassan-Alin M, Andersson T, Niazi M, Röhss K (2005) A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 60:779–784PubMedCrossRefGoogle Scholar
- 19.Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S (2006) Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Therapeutics 79:144–1452CrossRefGoogle Scholar
- 23.Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G (2005) Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 78:627–634PubMedCrossRefGoogle Scholar
- 26.Wagner JG (1979) Fundamentals of Clinical Pharmacokinetics, 2nd edn. Drug Intelligence Publications, Inc., Hamilton, IL, pp 36–7Google Scholar